US Stock MarketDetailed Quotes

GANX Gain Therapeutics

Watchlist

2.730
+0.170+6.64%

Close Feb 14 16:00 ET

2.780
+0.050+1.83%

Post 19:34 ET

72.41MMarket Cap-2.55P/E (TTM)

Gain Therapeutics Stock Forum

DDDDDDDDDDD

Dec 19, 2024 07:33

$Hoth Therapeutics (HOTH.US)$
$Gain Therapeutics (GANX.US)$
$Edible Garden (EDBL.US)$
All Short

Jaguar8

Dec 15, 2024 20:58

🔶December 2024 Upcoming Catalysts. Save it. In alphabetical order

$ABVC BioPharma (ABVC.US)$ - Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024.
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...

Stock_Drift

Nov 14, 2024 18:01

After Hours Ticks. 7:00pm

$Mercurity Fintech (MFH.US)$ $Freightos (CRGO.US)$ $1847 Holdings (EFSH.US)$ $MediciNova (MNOV.US)$ $Despegar.com (DESP.US)$ $NextPlat (NXPL.US)$ $Legacy Education (LGCY.US)$ $Gain Therapeutics (GANX.US)$ $Red Cat Holdings (RCAT.US)$ $Siyata Mobile (SYTA.US)$ $Innovation Beverage Group (IBG.US)$ $Greenidge Generation (GREE.US)$ $The Arena Group (AREN.US)$
📊⚡️📊

Stock_Drift

Oct 30, 2024 17:49

After Hours Ticks. 6:48pm

$Gain Therapeutics (GANX.US)$ $Orion Group (ORN.US)$ $Nextracker (NXT.US)$ $Alphatec (ATEC.US)$ $Remitly Global (RELY.US)$ $1847 Holdings (EFSH.US)$ $Carvana (CVNA.US)$ $Junee (JUNE.US)$ $Tenon Medical (TNON.US)$ $Aditxt (ADTX.US)$ $CPS Technologies (CPSH.US)$ $Root Inc (ROOT.US)$
📊⚡️📊

Jaguar8

Oct 7, 2024 06:01

NEWS

$Gain Therapeutics (GANX.US)$
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
Gain Therapeutics presented new preclinical data for GT-02287 at the Society for Neuroscience 2024 conference. The data demonstrates disease-modifying activity in both GBA-1 and idiopathic Parkinson's disease models. Key findings include:
1. Persistent rescue of motor and cognitive function after GT-02287 discontinuation
2. Improved mitochondrial function and neuroprotection in GBA1-Parkins...

Trytosaveabit

Sep 30, 2024 06:37

Update

$Gain Therapeutics (GANX.US)$ Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
Gain Therapeutics, Inc. Mon, Sep 30, 2024, 7:00 AM 7 min read
Gain Therapeutics, Inc.
GT-02287 Increases Peripheral GCase Activity
GT-02287 Demonstrates CNS Exposure